Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NATRECOR

« Back to Dashboard
Natrecor is a drug marketed by Scios Llc and is included in one NDA. It is available from one supplier.

The generic ingredient in NATRECOR is nesiritide recombinant. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nesiritide recombinant profile page.

Summary for Tradename: NATRECOR

Suppliers / Packagers: see list1

Pharmacology for Tradename: NATRECOR

Clinical Trials for: NATRECOR

Natrecor for Pulmonary Hypertension in Lung Transplants
Status: Completed Condition: Pulmonary Hypertension

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Status: Completed Condition: Congestive Heart Failure

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Status: Withdrawn Condition: Heart Failure, Congestive; Dyspnea; Pulmonary Edema

Natrecor in Pulmonary Hypertension
Status: Terminated Condition: Pulmonary Hypertension; Cancer; Lung Disease; Cardiothoracic Surgery

Use of Nesiritide in the Management of Acute Diastolic Heart Failure
Status: Terminated Condition: Heart Failure; Cardiovascular Disease; Acute Heart Failure; Diastolic Heart Failure; Congestive Heart Failure; Heart Disease

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery
Status: Terminated Condition: Heart Defects, Congenital

FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
Status: Completed Condition: Heart Failure, Congestive

A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
Status: Completed Condition: Cardiomyopathies; Heart Failure, Congestive; Dyspnea, Paroxysma

Nesiritide and Renal Function After the Total Artificial Heart
Status: Terminated Condition: Congestive Heart Failure; Cardiorenal Syndrome

Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
Status: Terminated Condition: Congestive Heart Failure; Cardiac Transplantation; Renal Insufficiency; Renal Failure

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scios Llc
nesiritide recombinant
FOR SOLUTION;INTRAVENOUS020920-001Aug 10, 2001RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn